Cargando…
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501917/ https://www.ncbi.nlm.nih.gov/pubmed/34628475 http://dx.doi.org/10.1038/s41391-021-00455-9 |
| _version_ | 1784580772153262080 |
|---|---|
| author | Liontos, Michalis Terpos, Evangelos Kunadis, Elena Zagouri, Flora Briasoulis, Alexandros Skafida, Efi Fiste, Oraianthi Markellos, Christos Andrikopoulou, Angeliki Gumeni, Sentiljana Kaparelou, Maria Koutsoukos, Konstantinos Gavriatopoulou, Maria Kastritis, Efstathios Trougakos, Ioannis P. Dimopoulos, Meletios- Athanasios |
| author_facet | Liontos, Michalis Terpos, Evangelos Kunadis, Elena Zagouri, Flora Briasoulis, Alexandros Skafida, Efi Fiste, Oraianthi Markellos, Christos Andrikopoulou, Angeliki Gumeni, Sentiljana Kaparelou, Maria Koutsoukos, Konstantinos Gavriatopoulou, Maria Kastritis, Efstathios Trougakos, Ioannis P. Dimopoulos, Meletios- Athanasios |
| author_sort | Liontos, Michalis |
| collection | PubMed |
| description | Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments like the androgen receptor-targeted agents (ARTA) that are commonly used in patients with metastatic prostate cancer. Herein, we report our data on 25 patients with prostate cancer under treatment with ARTA who were vaccinated for COVID-19. Our data suggest that these patients develop neutralizing antibodies against SARS-CoV-2 similarly to healthy volunteers. No safety issues were noted. |
| format | Online Article Text |
| id | pubmed-8501917 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85019172021-10-12 Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients Liontos, Michalis Terpos, Evangelos Kunadis, Elena Zagouri, Flora Briasoulis, Alexandros Skafida, Efi Fiste, Oraianthi Markellos, Christos Andrikopoulou, Angeliki Gumeni, Sentiljana Kaparelou, Maria Koutsoukos, Konstantinos Gavriatopoulou, Maria Kastritis, Efstathios Trougakos, Ioannis P. Dimopoulos, Meletios- Athanasios Prostate Cancer Prostatic Dis Brief Communication Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments like the androgen receptor-targeted agents (ARTA) that are commonly used in patients with metastatic prostate cancer. Herein, we report our data on 25 patients with prostate cancer under treatment with ARTA who were vaccinated for COVID-19. Our data suggest that these patients develop neutralizing antibodies against SARS-CoV-2 similarly to healthy volunteers. No safety issues were noted. Nature Publishing Group UK 2021-10-09 2022 /pmc/articles/PMC8501917/ /pubmed/34628475 http://dx.doi.org/10.1038/s41391-021-00455-9 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Brief Communication Liontos, Michalis Terpos, Evangelos Kunadis, Elena Zagouri, Flora Briasoulis, Alexandros Skafida, Efi Fiste, Oraianthi Markellos, Christos Andrikopoulou, Angeliki Gumeni, Sentiljana Kaparelou, Maria Koutsoukos, Konstantinos Gavriatopoulou, Maria Kastritis, Efstathios Trougakos, Ioannis P. Dimopoulos, Meletios- Athanasios Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title_full | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title_fullStr | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title_full_unstemmed | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title_short | Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients |
| title_sort | treatment with abiraterone or enzalutamide does not impair immunological response to covid-19 vaccination in prostate cancer patients |
| topic | Brief Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501917/ https://www.ncbi.nlm.nih.gov/pubmed/34628475 http://dx.doi.org/10.1038/s41391-021-00455-9 |
| work_keys_str_mv | AT liontosmichalis treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT terposevangelos treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT kunadiselena treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT zagouriflora treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT briasoulisalexandros treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT skafidaefi treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT fisteoraianthi treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT markelloschristos treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT andrikopoulouangeliki treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT gumenisentiljana treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT kapareloumaria treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT koutsoukoskonstantinos treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT gavriatopouloumaria treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT kastritisefstathios treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT trougakosioannisp treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients AT dimopoulosmeletiosathanasios treatmentwithabirateroneorenzalutamidedoesnotimpairimmunologicalresponsetocovid19vaccinationinprostatecancerpatients |